文献速递耳科与耳神经

COVID-19疫苗接种后突发性感音神经性听力损失的评估

Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项横断面研究和病例系列分析了美国疫苗不良事件报告系统(VAERS)在2020年12月14日至2021年7月16日期间收到的555例疑似突发性感音神经性听力损失(SSNHL)报告,并分析了21例接种COVID-19疫苗后发生SSNHL的患者。VAERS报告的年化发病率估计为每10万人年0.6至28.0例,与一般人群预期发病率相比,未提示疫苗接种与听力损失发病率增加存在关联。

要点

  • VAERS中555例SSNHL报告的年化发病率估计为每10万人年0.6至28.0例。
  • 三种疫苗的SSNHL报告率相似:辉瑞-BioNTech和Moderna均为每10万剂0.16例,强生为每10万剂0.22例。
  • 21例病例系列中,有治疗后听力资料的14例里8例(57.1%)治疗后改善。

核心结论

  • VAERS数据更新分析和接种COVID-19疫苗后发生SSNHL的病例系列未提示疫苗接种与听力损失发病率增加存在关联。

研究设计与样本

  • 横断面研究和病例系列,分析VAERS在2020年12月14日至2021年7月16日美国疫苗接种活动前7个月内的555例 probable SSNHL 事件报告。
  • 多机构回顾性病例系列纳入21例接种COVID-19疫苗后3周内发生SSNHL的成人患者,来自美国2个三级中心和1个社区诊所。

主要发现

  • VAERS 555例报告:平均年龄54岁(范围15-93岁),女性305例(55.0%),平均发病时间6天(范围0-21天)。
  • 年化发病率估计为每10万人年0.6至28.0例。
  • 三种疫苗的报告率:辉瑞-BioNTech和Moderna均为每10万剂0.16例,强生为每10万剂0.22例。
  • 病例系列21例:平均年龄61岁(范围23-92岁),女性13例(61.9%),平均发病时间6天(范围0-15天)。
  • 6例(28.6%)有预先存在的自身免疫性疾病;有治疗后听力资料的14例中8例(57.1%)改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Emerging reports of sudden sensorineural hearing loss (SSNHL) after COVID-19 vaccination within the otolaryngological community and the public have raised concern about a possible association between COVID-19 vaccination and the development of SSNHL. OBJECTIVE: To examine the potential association between COVID-19 vaccination and SSNHL. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study and case series involved an up-to-date population-based analysis of 555 incident reports of probable SSNHL in the Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System (VAERS) over the first 7 months of the US vaccination campaign (December 14, 2020, through July 16, 2021). In addition, data from a multi-institutional retrospective case series of 21 patients who developed SSNHL after COVID-19 vaccination were analyzed. The study included all adults experiencing SSNHL within 3 weeks of COVID-19 vaccination who submitted reports to VAERS and consecutive adult patients presenting to 2 tertiary care centers and 1 community practice in the US who were diagnosed with SSNHL within 3 weeks of COVID-19 vaccination. EXPOSURES: Receipt of a COVID-19 vaccine produced by any of the 3 vaccine manufacturers (Pfizer-BioNTech, Moderna, or Janssen/Johnson & Johnson) used in the US. MAIN OUTCOMES AND MEASURES: Incidence of reports of SSNHL after COVID-19 vaccination recorded in VAERS and clinical characteristics of adult patients presenting with SSNHL after COVID-19 vaccination. RESULTS: A total of 555 incident reports in VAERS (mean patient age, 54 years [range, 15-93 years]; 305 women [55.0%]; data on race and ethnicity not available in VAERS) met the definition of probable SSNHL (mean time to onset, 6 days [range, 0-21 days]) over the period investigated, representing an annualized incidence estimate of 0.6 to 28.0 cases of SSNHL per 100 000 people per year. The rate of incident reports of SSNHL was similar across all 3 vaccine manufacturers (0.16 cases per 100 000 doses for both Pfizer-BioNTech and Moderna vaccines, and 0.22 cases per 100 000 doses for Janssen/Johnson & Johnson vaccine). The case series included 21 patients (mean age, 61 years [range, 23-92 years]; 13 women [61.9%]) with SSNHL, with a mean time to onset of 6 days (range, 0-15 days). Patients were heterogeneous with respect to clinical and demographic characteristics. Preexisting autoimmune disease was present in 6 patients (28.6%). Of the 14 patients with posttreatment audiometric data, 8 (57.1%) experienced improvement after receiving treatment. One patient experienced SSNHL 14 days after receiving each dose of the Pfizer-BioNTech vaccine. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, findings from an updated analysis of VAERS data and a case series of patients who experienced SSNHL after COVID-19 vaccination did not suggest an association between COVID-19 vaccination and an increased incidence of hearing loss compared with the expected incidence in the general population.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Formeister EJ, Wu MJ, Chari DA, et al. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35201274. doi:10.1001/jamaoto.2021.4414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。